The Licensed Ebola Vaccine Was Never Proven to Stop the Strain Now Killing Congo

In 2019 the FDA licensed Ervebo, a single-dose Ebola vaccine that had performed so well in a ring-vaccination trial in Guinea that public-health officials started talking about the virus in the past tense. The method came straight out of smallpox eradication: find a case, vaccinate the ring of contacts around it, then everyone those people touched, and starve the virus of new hosts. It worked against Zaire ebolavirus, the species behind most of the large outbreaks, including the 2018-2020 epidemic in eastern Congo. Against the species now killing that same region, it does nothing anyone has been able to measure.

Congo declared the current outbreak on May 15, and it is not Zaire. It is Bundibugyo virus, a separate member of the Ebola family first identified in a 2007 outbreak in western Uganda, and it has become the fastest-growing Ebola outbreak on record. Ervebo protects against exactly one member of that family, Zaire, and has never been proven to protect against the others, Bundibugyo included. For nearly twenty years that limitation sat in the scientific literature as a technicality. In Ituri province it is now the difference between a controllable outbreak and this one.

The numbers explain why. As of this week the Africa Centres for Disease Control counts 3,802 cases and 1,707 deaths, a case-fatality rate near 45 percent, with nearly 90 percent of cases concentrated in Ituri. The 2014-2016 West Africa epidemic, the largest in history, took roughly eight months to reach 1,000 deaths. This outbreak passed 1,700 in under three months.

Here the celebrated vaccine runs into the wall of the wrong virus. In late May a WHO expert panel reviewed whether Ervebo cross-protects against Bundibugyo and found the data too limited to estimate any effectiveness at all. Its guidance was blunt: do not deploy Ervebo programmatically against a Bundibugyo outbreak outside a controlled study. There is no approved vaccine for this virus and no approved treatment. The two monoclonal-antibody drugs that cut mortality in a landmark 2018 Zaire trial were built against that species, and no one has shown they work here.

So responders in Ituri are fighting a 2026 outbreak with the tools of a decade ago: isolate the sick, trace their contacts, bury the dead safely. And the tracing, the intervention that has always been the real backbone of Ebola control, has broken down. Africa CDC Director-General Jean Kaseya said it plainly this week: contact tracing “is not working,” with 60 to 70 percent of new cases now surfacing from community spread rather than known contacts. When two-thirds of infections appear outside the lists you are watching, you are not containing an outbreak. You are counting it.

The reasons are partly the brutal geography that has haunted eastern Congo for years: armed groups, mass displacement, a population with hard-earned reasons to distrust outsiders in hazmat suits. But part is grimly mundane. More than 100 health workers have been infected. Others in Bunia struck over unpaid wages and unsafe conditions, and workers in Mongbwalu issued a 24-hour ultimatum over paychecks that had stopped coming, in the middle of the fastest-growing Ebola outbreak on record. A workforce that is sick, dead, or unpaid cannot run contact tracing across an entire province.

Washington’s version of the story arrives here, and it deserves a harder look than it usually gets. Aid groups have spent the spring blaming the U.S. retreat, and the collapse is documented: American assistance to Congo fell to about $67 million in the final quarter of 2025, down from $715 million the year before and nearly $1.2 billion the year before that, according to federal funding databases and disclosures the administration submitted to Congress. The money left, and the response cracked.

But that framing quietly assumes the earlier arrangement was working, and it wasn’t. A response where one donor’s withdrawal collapses the entire apparatus, where frontline workers strike over back pay while OCHA releases up to $60 million through the UN’s central emergency fund and the WHO convenes panels, is not a functioning system that lost its patron. It is a dependency wearing the costume of a safety net. The lesson of Ituri is not that the global-health machine needs more money to run the same routine. It is that a country cannot outsource its own biosecurity to a pipeline a distant budget fight can switch off, and that the officials who spent a decade describing Ebola as a solved problem were describing a fix that only ever covered one species out of several.

The scramble now is to build the vaccine that should have existed years ago. A first Bundibugyo-specific candidate entered Phase 1 human trials in the U.K. on July 24, with a parallel Canadian trial opening this week, and an oral post-exposure drug is being tested in more than 25 high-risk contacts in Ituri itself. The work matters. It is also, for the people dying in Bunia this month, too late: a Phase 1 trial measures safety in healthy volunteers, and any usable result is months away. Whatever emerges will be a tool for the next Bundibugyo outbreak, not this one.

So watch two things in the coming weeks. The first is whether the case count keeps accelerating; it will signal victory or defeat before any official announcement does. The second is the readout from those post-exposure trials in Ituri, the only intervention that could bend this curve before a vaccine exists. Everything else, the pledges, the panels, the emergency funds, is the same machinery that assured the world, once before, that this was handled.

Sources

1. STAT News – Ebola kills 1,700 in eastern Congo as the fastest-growing outbreak surges (Aug 4, 2026)
2. WHO – Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus (May 28, 2026)
3. National Academies – Does the current Ebola vaccine protect against every type of Ebola virus?
4. UN News – New Ebola vaccine trial launches as outbreak spreads in DR Congo (Aug 2026)
5. Doctors Without Borders – Bundibugyo virus: why this Ebola disease outbreak is different
6. STAT News – Trump’s cuts to foreign aid are undermining the Ebola response, insiders say (May 19, 2026)